Masitinib for ALS: AB10015 Reports 42.3% 5-Year Survival
A 2026 AB10015 post-hoc preprint reported 42.3% 5-year survival from amyotrophic lateral sclerosis symptom onset among patients originally assigned to masitinib 4.5 mg/kg/day with riluzole. …
Read article